# Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity

> **NCT07572175** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 60 (estimated)

## Conditions studied

- Anthracycline-induced Cardiotoxicity
- Lymphoma
- Chemotherapy
- Cardiotoxicity

## Interventions

- **DRUG:** Sotagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07572175
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2029-06
- **Final completion:** 2029-10
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07572175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07572175, "Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07572175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*